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Abstract
Background: Rapidly progressive glomerulonephritis has been described in dogs that
seroreact to Borrelia burgdorferi, but no studies have compared clinicopathologic dif-
ferences in Lyme-seroreactive dogs with protein-losing nephropathy (PLN) versus
dogs with Borrelia-seronegative PLN.
Hypothesis/Objectives: Dogs with Borrelia C6 antigen-seroreactive PLN have dis-
tinct clinicopathologic findings when compared to dogs with Borrelia seronega-
tive PLN.
Animals: Forty dogs with PLN and Borrelia C6 antigen seroreactivity and 78
C6-seronegative temporally matched dogs with PLN.
Methods: Retrospective prevalence case-control study. Clinical information was
retrieved from records of dogs examined at the University of California, Davis, Veter-
inary Medical Teaching Hospital. Histopathologic findings in renal tissue procured by
biopsy or necropsy of dogs with PLN were reviewed.
Results: Retrievers and retriever mixes were overrepresented in seroreactive dogs
(P < .001). Seroreactive dogs were more likely to have thrombocytopenia (P < .001),
azotemia (P = .002), hyperphosphatemia (P < .001), anemia (P < .001), and neutrophilia
(P = .003). Hematuria, glucosuria, and pyuria despite negative urine culture were more
likely in seroreactive dogs (all P ≤ .002). Histopathologic findings were consistent with
immune-complex glomerulonephritis in 16 of 16 case dogs and 7 of 23 control dogs
(P = 006). Prevalence of polyarthritis was not different between groups (P = .17).
Conclusions and Clinical Importance: C6 seroreactivity in dogs with PLN is associ-
ated with a clinicopathologically distinct syndrome when compared with other types
of PLN. Early recognition of this syndrome has the potential to improve outcomes
through specific aggressive and early treatment.
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glomerulonephritis; PLN, protein-losing nephropathy; UPCR, urine protein:creatinine ratio; VMTH, Veterinary Medical Teaching Hospital.
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1 | INTRODUCTION
The diagnosis of Lyme borreliosis remains challenging for veterinary
practitioners presented with dogs with polyarthritis or protein-losing
nephropathy (PLN). Similarly, Lyme disease is the most commonly
reported tick-borne disease in humans in the United States,1 but proving
a correlation between positive serologic testing and Lyme disease is diffi-
cult. The distribution of Lyme disease in the United States is largely deter-
mined by its 2 primary tick vectors, Ixodes scapularis and Ixodes pacificus,
and is concentrated in the northeast and upper midwest, and along the
Pacific coast. In these areas, up to 40% of healthy dogs may test positive
for antibodies to Borrelia burgdorferi,2-4 but only a small percentage
(<10%) of infected dogs are believed to develop clinical signs of disease.5,6
Because organisms are present in very low numbers in connective tissue
and are difficult to detect using culture or molecular techniques, diagnosis
of acute Lyme borreliosis relies on a combination of characteristic clinical
signs (polyarthritis, fever, inappetence), exclusion of other systemic dis-
eases, and seroreactivity to Borrelia antigens. The B. burgdorferi C6 pep-
tide antigen is a portion of the spirochete VlsE surface protein and has
been a popular target for serologic assays, because it is only expressed in
the host during active infection.7
The extended time course of the disease makes it even more difficult
for practitioners to associate chronic disorders with Borrelia infection.
Rheumatologic, neurologic, and cardiac complications have been recog-
nized in humans.8-10 Correlations with fibromyalgia, memory impairment,
and chronic fatigue also have been proposed in the human medical liter-
ature, but the diagnosis of “chronic Lyme disease” remains controver-
sial.9,11,12 All these conditions are poorly documented in dogs with
borreliosis.13-15 Conversely, a syndrome of severe PLN (“Lyme nephritis”)
is believed to occur in 5%-10% of affected dogs, whereas reports of sim-
ilar renal complications in human patients are rare.16,17
Lyme nephritis is a syndrome of rapidly progressive membrano-
proliferative glomerulonephritis in Borrelia-seroreactive dogs that was first
described in 1997.18 Dogs with Lyme nephritis were significantly younger
than dogs with other types of glomerulonephritis, and Golden Retrievers
and Labrador Retrievers were overrepresented. Clinicopathologic findings
were not described in that study, and to our knowledge, no other studies
that compare findings in dogs with suspected Lyme nephritis to findings in
dogs with other causes of PLN have been undertaken to date.
We have observed that thrombocytopenia and concurrent poly-
arthritis are often present in dogs with Borrelia C6 antigen-positive
PLN but appear to be uncommon in dogs with other types of PLN.
Therefore, our goal was to determine whether dogs in northern Cali-
fornia with PLN that were seroreactive to the Borrelia C6 antigen had
distinct clinicopathologic abnormalities that distinguished them from
dogs with PLN that were seronegative for the Borrelia C6 antigen. We
hypothesized that platelet counts would be lower in seroreactive dogs
as compared to seronegative dogs, and that the prevalence of poly-
arthritis would be higher in seroreactive dogs. With this study, we
aimed to strengthen the existing evidence that Lyme nephritis is a
unique clinical syndrome and to identify clinicopathologic abnormali-
ties that might assist in the early recognition of the disease.
2 | MATERIALS AND METHODS
This study was a retrospective prevalence case-control study. All dogs
evaluated at the VeterinaryMedical TeachingHospital (VMTH) at theUni-
versity of California, Davis, between January 2002 and December 2015,
were eligible for inclusion. Electronic medical records were searched for
dogs evaluated for PLN that also had vector-borne disease serology per-
formed that included a C6 peptide antibody test (Quantitative C6, SNAP
3DX, SNAP 4DX, and SNAP 4DX Plus, IDEXX Laboratories, Portland,
Maine) within 1 month of first being evaluated. For every dog identified
with PLN seroreactive for Borrelia, 2 temporally associated seronegative
control dogs evaluated for PLN were selected for comparison—the dogs
seen immediately before and after the seroreactive case (ie, 2 controls for
each case). Additional inclusion criteria for all case and control dogswere a
urine protein:creatinine ratio (UPCR) >5 or histologically confirmed glo-
merulonephritis. Dogs were excluded if results of a UPCR performed
within 1 month of initial evaluation were not available. Patient age, breed,
sex, body weight, rectal temperature at the time of evaluation, clinical
signs, and date of onset of illness were recorded. Where performed,
results of blood pressure evaluation were recorded and classified as
hypertensive (systolic pressure >160 mmHg) or normotensive. Results of
a CBC, serum biochemistry panel, urinalysis, aerobic bacterial urine cul-
ture, and serologic testing for other vector-borne diseases, performed
within 1 month of initial evaluation, either at the VMTHor at a commercial
veterinary diagnostic laboratory, were collected.When the same tests had
been performed multiple times, the test performed closest to the time of
initial examination for PLN at the VMTHwas selected for analysis. Hema-
tologic and biochemical variableswere compared to their reference ranges
at the time of sample collection (which varied over the study period) to
define results as within, above, or below reference ranges. For urinalysis
results, microscopic hematuria was defined as ≥10 red blood cells/hpf,
and pyuria was defined as ≥5 white blood cells/hpf. Evidence of concur-
rent polyarthritis was noted; this evidence included either results of syno-
vial fluid analysis documenting neutrophilic inflammation or at least 3 of
the following physical examination findings: fever, stiff gait, lameness, joint
swelling or effusion, or pain on joint palpation or manipulation. All renal
histopathologic findings (obtained by renal biopsy or at necropsy) were
recorded. Finally, last known outcome was determined based on medical
records and recorded owner communications.
2.1 | Renal histopathology
Available biopsy specimens were classified as consistent or inconsistent
with a diagnosis of immune complex glomerulonephritis (ICGN) using
criteria similar to those previously published.19 In brief, specimens submit-
ted to the University of California, Davis Anatomic Pathology service, were
fixed in 10% buffered formalin for histologic analysis. Paraffin-embedded
tissues then were sectioned at 5 μm thickness and stained routinely with
hematoxylin and eosin. Additional sections were prepared for examination
by Masson's trichrome staining, periodic acid Schiff reaction, or Jones
methenamine silver method. All microscopic sections were evaluated by a
board-certified veterinary anatomic pathologist (F.C.M.). Where biopsy
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specimens hadbeen submitted to the InternationalVeterinaryRenal Pathol-
ogy Service, available histopathologic imageswere reviewed retrospectively
by the same pathologist (F.C.M.). Histologic features suggestive of a diagno-
sis of ICGN were hypercellularity in the peripheral aspects of glomerular
lobules and the mesangium; glomerular basement membrane thickening,
duplication, remodeling, spikes, and holes; intracapillary neutrophils; nuclear
pyknosis; andmesangial matrix expansion.When available, evidence for the
presence of glomerular immune complex deposits also was evaluated by
transmission electron microscopy and immunofluorescence microscopy.
Dogswith other findingswere classified as non-ICGNcases.
2.2 | Statistical analysis
Descriptive statistics were calculated; normally distributed variables were
expressed as mean ± standard deviation, and those not normally distrib-
uted were expressed as median (range). Categorical data were expressed
as frequencies; values with a nonlinear distribution were analyzed cate-
gorically. Fisher's exact test was used to compare categorical variables.
Conditional univariate logistic regression was used to estimate matched
odds ratios and 95%confidence intervals (CI) relating individual blood vari-
ables to being diagnosed as a case versus a control. For histopathologic
classification, the odds ratio was inestimable using conventional condi-
tional logistic regression, and therefore exact conditional logistic regres-
sion was used. A specification link test for single-equation models (link
test, Stata, version 11; StataCorp, College Station, Texas) was used to
screen for specification errors when using linear quantitative variables. All
analyses were performed using commercial statistical software (Stata, ver-
sion 11; StataCorp).
3 | RESULTS
In all, 40 dogs with Borrelia C6-antigen seroreactive PLN were identi-
fied for inclusion, along with 78 temporally matched control dogs.
Two of the cases had only 1 control dog identified because of insuffi-
cient numbers of control dogs evaluated between cases. Differences
in categorical variables between cases and controls are shown in
Table 1, and continuous variables are shown in Table 2.
Among seroreactive dogs, the most common breeds were Labrador
Retrievers (13/40) or Labrador mixes (4/40), Golden Retrievers (4/40)
or mixes (1/40), and Australian Shepherds (3/40) or mixes (1/40). Con-
trols similarly were distributed across a variety of breeds, the most
common of which were Labrador Retrievers (5/78) or mixes (1/78),
American Cocker Spaniels (5/78) or mixes (2/78), Yorkshire Terriers
(5/78), and Golden Retrievers (4/78). When Labrador and Golden
Retrievers were considered together (“retrievers”; see Table 1), these
breeds were overrepresented in the case group. This was true when
purebreds were considered alone (P = .001) or when purebreds and
mixes were considered together (P < .001).
The median duration of clinical signs before initial examination was
19.0 days for seronegative dogs and 18.5 days for seroreactive dogs
(P = .10). Reported clinical signs were inappetence (29/78 controls,
31/40 cases, P < .001), lethargy or weakness (32/78 controls, 25/40
cases, P = .049), vomiting (20/78 controls, 27/40 cases, P < .001),
weight loss (14/78 controls, 12/40 cases, P = .18), increased thirst and
urination (12/78 controls, 2/40 cases, P = .17), diarrhea (10/78 con-
trols, 3/40 cases, P = .58), joint pain or lameness (6/78 controls, 6/40
cases, P = .37), ascites or peripheral edema (8/78 controls, 0/40 cases,
P = .059), and respiratory signs (4/78 controls, 2/40 cases, P = 1.0).
Blood pressure evaluation was performed in 68 of 78 seronegative
and 39 of 40 seroreactive dogs. Results were considered consistent
with the presence of systemic hypertension in 48 of 68 (70.6%) sero-
negative dogs and 33 of 39 (84.6%, P = .20) seroreactive dogs.
Low numbers of dogs overall had evidence of polyarthritis at the
time of examination (8/40 cases, 7/78 controls, P = .17; Table 1). Physi-
cal examination findings consistent with polyarthritis were pain on joint
palpation or manipulation (4/7 controls, 3/8 cases), joint swelling or
effusion (2/7 controls, 4/8 cases), lameness (1/7 controls, 4/8 cases),
stiff gait (2/7 controls, 3/8 cases), fever (1/7 controls, 2/8 cases), spinal
pain (1/7 controls), and abnormal stance (1/7 controls). Polyarthritis
was confirmed by identification of nonseptic, suppurative inflammation
in synovial fluid specimens in 5 of 8 cases and 6 of 7 controls.
Complete blood count and urinalysis data were available for 39 of
40 cases and all controls, and serum biochemistry panel and UPCR
results were available for all cases and controls (Tables 1 and 2). Mean
hematocrit was lower (27.0% versus 38.2%, P < .001) and mean cor-
puscular volume (MCV) was higher (72.7 versus 70.1, P = .005) for
cases as compared to controls, although mean MCV remained within
reference ranges for both groups. White blood cell counts were
nonlinearly distributed, but the proportion of dogs with leukocytosis
or leukopenia did not differ between the 2 groups (Table 1). A few
dogs in either group had increased numbers of band neutrophils (9/39
cases, 13/78 controls), which typically was mild. Lymphopenia and
thrombocytopenia occurred more often in cases than in controls
(P = .006 and <.001, respectively), and mean lymphocyte and platelet
counts also were lower in case dogs (P = .03 and <.001, respectively).
Where present, thrombocytopenia generally was mild to moderate
(50 000-150 000 platelets/μL). However, 9 of 26 dogs had platelet
counts ≤50 000/μL; 2 of these dogs were controls.
Nearly all dogs in the C6-seroreactive group (38/40) had a serum
creatinine concentration above the reference range (>2.2 mg/dL), com-
pared to just over half of the controls (41/78, P = .002; Table 1). Simi-
larly, mean serum urea nitrogen concentration was higher in cases
(101.8 mg/dL) as compared to controls (61.7 mg/dL, P < .001; Table 2).
Serum phosphorus and potassium concentrations both were higher in
cases as compared to controls (P < .001 and .04, respectively), whereas
serum albumin concentration was lower in cases (P = .004).
Glucosuria, hematuria, and pyuria were more prevalent in cases than
in controls (P < .01 for all; Table 1). Urine protein:creatinine ratios did
not differ between the 2 groups. Results of aerobic bacterial urine cul-
ture were available for 38 of 40 cases and 74 of 78 controls and were
positive in only 1 case dog with growth of >105 cfu/mL Escherichia coli.
Results of testing for other infectious diseases are shown in Table 3.
One case dog seroreacted to Ehrlichia canis (1:100) and Rickettsia rickettsii
(1:25). The other case dog that seroreacted to R. rickettsii had a titer of
1:320 with no other identified exposure to co-pathogens (negative for
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heartworm antigen, and for antibodies to Ehrlichia, Babesia, andAnaplasma).
Six case dogs seroreacted to Anaplasma antigens. Titers were determined
for 4 dogs and were 1:640, 1:80, 1:20, and 1:20; none had other known
exposures. The single control dog that seroreacted to R. rickettsii (1:160)
also seroreacted to Babesia vogeli (titer 1:80). The 4 control dogs that ser-
oreacted to E. canis had titers that ranged from 1:10240 to 1:327680; 2 of
these dogs also seroreacted to Anaplasma spp.
The only comorbid disease identified in the case dogs was a hepatic
mass of unknown type in 1 dog. Among control dogs, 6 dogs had neopla-
sia (2 with lymphoma, 2 with mast cell tumors, and 1 each with peripheral
nerve sheath tumor, osteochondroma, osteosarcoma, and a complex
splenic mass). Three control dogs had central nervous system disease
(2 with myelopathies, and 1 with inflammatory brain disease), and 3 con-
trol dogs had endocrine disease (1 each with diabetes mellitus, pituitary-
dependent hyperadrenocorticism, and inappropriate erythropoietin
production). Other diseases in the control dogs included a chronic jeju-
nal intussusception and a perivulvar abscess.
In the 14 days before examination at the VMTH, 31 of 40 case dogs
and 48 of 78 control dogs were treated with ≥1 anti-infective agents
(P = .10), and 11 of 40 cases and 24 of 78 controls were treated with an
anti-inflammatory or immunosuppressive agent (P = .71; Table 4).
Renal biopsy, necropsy, or both was performed in 19 cases and
29 controls. Nine dogs (3 cases and 6 controls) were excluded from
assessment of histopathology findings because of missing or non-
diagnostic biopsy samples upon review. Renal specimens from all
16 case dogs were classified as consistent with ICGN, as compared to
7 of 23 specimens from controls (P = .06). The remaining control dogs
had amyloidosis (6), glomerulosclerosis (4), or a variety of findings that
were inconsistent with ICGN (6). If dogs with membranous glomerulo-
nephritis (MGN) were removed from the ICGN category, 15 of 16 cases
and 3 of 23 controls were classified as having ICGN (P = .06, OR, 7.58;
95% CI, 0.90-63.94).
The last documented outcome was recorded for all dogs. For cases,
13 of 40 dogs were documented as alive at a median of 72 days after
TABLE 1 Results of analysis of categorical variables comparing 40 dogs with Borrelia C6-antigen seroreactive PLN and 78 dogs with Borrelia
C6-antigen PLN. ICGN, immune-complex glomerulonephritis
Borrelia C6 seroreactive Borrelia C6 seronegative OR 95% CI P value
Age ≤8 27/40 44/78 1.69 0.74-3.90 .22
Male sex 15/40 42/78 0.50 0.22-1.12 .09
Intact 6/40 13/78 0.81 0.27-2.46 .72
Rectal temperature ≥102.5 (F) 4/40 7/78 1.18 0.30-4.63 .81
Retriever
Purebred 17/40 9/78 5.53 2.01-15.22 .001
Purebred or mix 22/40 10/78 7.22 2.70-19.30 <.001
Hypertension 33/39 48/68 2.05 0.75-6.59 .20
Polyarthritis 8/40 7/78 2.55 0.71-10.19 .17
ICGN 16/16 7/23 7.30 0.96-∞ .06
CBC
Anemia 37/39 46/78 11.33 2.61-49.17 .001
Thrombocytopenia 26/38 9/75 14.55 4.36-48.54 <.001
Leukocytosis 20/39 27/78 2.00 0.90-4.23 .09
Leukopenia 3/39 3/78 2.00 0.40-9.91 .40
Neutrophilia 23/39 22/78 3.82 1.58-9.23 .003
Lymphopenia 18/39 17/78 3.79 1.46-9.87 .006
Biochemistry
Creatinine ≥2.2 38/40 41/78 24.67 3.30-184.36 .002
Hyperphosphatemia 37/40 32/78 17.14 4.02-72.97 <.001
Hyperkalemia 11/40 12/78 2.50 0.88-7.11 .09
Hypoalbuminemia 38/40 63/78 4.56 0.98-21.35 .05
Hyperglobulinemia 6/40 8/77 1.55 0.51-4.69 .44
Urinalysis
Glucosuria 19/39 10/78 9.33 2.71-32.14 <.001
Hematuria 19/39 16/78 4.32 1.68-11.11 .002
Pyuria 12/39 0/78 33.63 5.55-∞ <.001
Cylindruria 22/39 33/78 1.85 0.82-4.14 .14
Abbreviations: OR, odds ratio. CI, confidence interval.
BORYS ET AL. 2099
T
A
B
L
E
2
R
es
ul
ts
o
f
an
al
ys
is
o
f
co
nt
in
uo
us
va
ri
ab
le
s
co
m
pa
ri
ng
si
gn
al
m
en
t,
he
m
at
o
lo
gi
c,
se
ru
m
bi
o
ch
em
is
tr
y
an
al
ys
is
,a
nd
ur
in
al
ys
is
fi
n
d
in
gs
in
4
0
d
o
gs
w
it
h
B
or
re
lia
C
6
-a
nt
ig
en
se
ro
re
ac
ti
ve
P
LN
an
d
7
8
do
gs
w
it
h
B
or
re
lia
C
6
-a
nt
ig
en
se
ro
ne
ga
ti
ve
P
LN
V
ar
ia
bl
e
(u
ni
t)
R
ef
.r
an
ge
B
or
re
lia
C
6
se
ro
re
ac
ti
ve
B
or
re
lia
C
6
se
ro
ne
ga
ti
ve
O
R
9
5
%
C
I
P
va
lu
e
R
an
ge
M
ea
n
M
ed
ia
n
R
an
ge
M
ea
n
M
ed
ia
n
A
ge
(y
)
N
A
3
.0
-1
1
.9
7
.0
6
.5
0
.4
-1
8
.3
7
.8
7
.6
N
L
B
o
dy
w
ei
gh
t
(k
g)
N
A
5
.9
-6
4
.0
2
4
.8
2
4
.7
1
.8
-6
3
.0
2
0
.5
2
0
.3
1
.0
3
1
.0
0
-1
.0
6
.0
9
R
ec
ta
lt
em
pe
ra
tu
re
(
F
)
9
9
.0
-1
0
2
.5
9
8
.0
-1
0
4
.5
1
0
1
.0
1
0
1
.0
9
8
.3
-1
0
4
.1
1
0
1
.2
1
0
1
.2
0
.8
8
0
.6
4
-1
.2
2
.4
5
D
ur
at
io
n
o
f
cl
in
ic
al
si
gn
s
(d
ay
s)
N
A
1
–1
6
0
3
4
.8
1
8
.5
0
-4
9
8
6
0
.7
1
9
.0
0
.9
9
0
.9
9
-1
.0
0
.1
0
C
B
C H
C
T
(%
)
4
0
-5
5
1
0
.9
-4
7
.1
2
7
.1
2
8
.5
1
4
.0
-6
2
.1
3
8
.3
3
7
.1
0
.8
9
0
.8
4
-0
.9
5
<
.0
0
1
M
C
V
6
5
-7
5
6
2
.5
-8
5
.8
7
2
.7
7
2
.7
5
9
.2
-8
0
.2
7
0
.1
7
0
.4
1
.2
1
.0
5
-1
.3
3
.0
0
5
M
C
H
C
3
3
-3
6
3
1
.2
-3
6
.4
3
4
.0
3
3
.9
2
7
.8
-3
7
.8
3
4
.4
3
4
.6
0
.8
0
0
.5
9
-1
.0
9
.1
6
W
B
C
(×
1
0
0
0
)
6
.0
-1
3
.0
4
.4
-4
4
.1
1
6
.0
1
3
.4
4
.4
-5
8
.8
1
3
.2
1
0
.2
N
L
N
eu
tr
o
ph
ils
(×
1
0
0
0
)
3
.0
-1
0
.5
3
.5
-4
0
.5
1
3
.7
1
1
.1
2
.7
-5
5
.7
1
0
.3
7
.6
N
L
B
an
ds
R
ar
e
0
-2
9
2
1
2
2
9
.0
0
0
-1
3
5
3
9
7
.6
0
1
.0
0
1
.0
0
-1
.0
0
.1
2
Ly
m
ph
o
cy
te
s
(×
1
0
0
)
1
0
-4
0
2
.2
-3
1
.6
1
1
.8
1
0
.1
1
.6
-6
7
.4
1
5
.9
1
4
.0
0
.9
4
0
.8
8
-1
.0
0
.0
3
P
la
te
le
ts
(×
1
0
,0
0
0
)
1
5
-4
0
2
.8
-5
4
.2
1
5
.1
1
0
.4
0
.8
-8
4
.4
3
5
.7
3
1
.9
0
.9
2
0
.8
9
-0
.9
6
<
.0
0
1
M
P
V
7
-1
3
7
.4
-2
1
.2
1
3
.1
1
2
.7
5
.8
-2
0
.5
1
1
.0
1
0
.3
1
.2
3
1
.0
7
-1
.4
2
.0
0
5
B
io
ch
em
is
tr
y
A
lb
um
in
3
.4
-4
.3
1
.2
-3
.7
2
.0
2
.0
1
.0
-4
.3
2
.4
2
.4
0
.3
3
0
.0
2
-0
.7
0
.0
0
4
G
lo
bu
lin
s
1
.7
-3
.1
1
.9
-5
.1
3
.0
2
.8
0
.9
-8
.8
2
.8
2
.6
N
L
So
di
um
1
4
3
-1
5
1
1
2
9
-1
6
2
1
4
7
.4
1
4
6
.5
1
3
5
-1
6
8
1
4
7
.6
1
4
7
0
.9
9
0
.9
1
-1
.0
7
.7
4
P
o
ta
ss
iu
m
3
.6
-4
.8
3
.2
-7
.0
4
.8
4
.8
3
.2
-6
.5
4
.5
4
.6
1
.7
3
1
.0
2
-2
.9
3
.0
4
C
al
ci
um
9
.6
-1
1
.2
7
.9
-1
4
.1
9
.8
9
.8
7
.7
-1
2
.0
1
0
.0
9
.9
0
.9
0
0
.6
5
-1
.2
5
.5
3
B
U
N
(×
1
0
)
1
.1
-3
.3
1
.7
-2
5
.7
1
0
.2
9
.8
0
.8
-1
7
.2
6
.2
5
.2
1
.2
1
.1
1
-1
.3
8
<
.0
0
1
C
re
at
in
in
e
0
.8
-2
.2
0
.7
-1
1
.9
5
.4
5
.0
0
.3
-1
3
.2
2
.9
1
.8
N
L
P
ho
sp
ho
ru
s
2
.6
-5
.2
4
.3
-2
6
.0
1
4
.5
1
3
.5
0
.9
-1
8
.6
6
.7
5
.6
1
.3
3
1
.1
7
-1
.5
1
<
.0
0
1
U
ri
na
ly
si
s
Sp
ec
if
ic
gr
av
it
y
≥
1
.0
2
5
1
.0
1
0
-1
.0
3
6
1
.0
1
8
1
.0
1
7
1
.0
0
6
-1
.0
5
7
1
.0
1
8
1
.0
1
5
N
L
U
P
C
R
≤
0
.4
3
.8
-2
7
.1
1
3
.8
1
2
.9
5
.0
-6
4
.4
1
4
.6
1
1
.4
0
.9
9
0
.9
5
-1
.0
3
.5
3
A
bb
re
vi
at
io
ns
:B
U
N
,b
lo
o
d
ur
ea
ni
tr
o
ge
n;
C
I,
co
nf
id
en
ce
in
te
rv
al
;H
C
T
,h
em
at
o
cr
it
;M
C
H
C
,m
ea
n
ce
ll
he
m
o
gl
o
bi
n
co
nc
en
tr
at
io
n;
M
C
V
,m
ea
n
co
rp
u
sc
u
la
r
vo
lu
m
e;
M
P
V
,m
ea
n
p
la
te
le
t
vo
lu
m
e;
N
L,
n
o
n
lin
ea
r;
O
R
,o
dd
s
ra
ti
o
;U
P
C
R
,u
ri
ne
pr
o
te
in
:c
re
at
in
in
e
ra
ti
o
;W
B
C
,w
hi
te
b
lo
o
d
ce
lls
.
2100 BORYS ET AL.
diagnosis (range, 2-706 days). Of these 13 dogs, 2 had progression of
their renal disease, 5 had improved or stable disease, and 6 of 13 had
unknown renal status. The remaining 27 dogs died or were euthanized
at a median of 7 days after diagnosis (range, 0-965 days); 25 of 27 of
these dogs had progressive renal disease. The other 2 dogs had stable
renal disease and died of unrelated causes (lymphoma, hepatic mass).
Among controls, 40 dogs were alive a median of 64 days after diagnosis
(range, 1-1619 days); 9 were known to have progressive renal disease,
10 had improved or stable disease, and 21 had unknown renal status.
The remaining 38 dogs died or were euthanized at a median of 42 days
after diagnosis (range, 1-2341 days); 36 of 38 had progressive renal dis-
ease. One of the other 2 dogs was euthanized for upper airway
obstruction, and the other was reported to have died with no further
information provided. There was no difference among groups in days
to last known outcome (P = .12) or in overall number of dogs experienc-
ing death or euthanasia (P = .08).
4 | DISCUSSION
Our results suggest that a unique set of clinicopathologic abnormali-
ties is present in dogs with Lyme C6 seroreactive PLN as compared to
other types of PLN. When Lyme nephritis was first described in dogs,
the existence of an association between seroreactivity and nephritis
was questioned because of the high prevalence of subclinical ser-
oreactivity to B. burgdorferi in endemic areas. Although assays that
target the Lyme C6 antigen have overcome problems associated with
vaccine and nonspecific cross-reactivity that were observed with
Borrelia immunofluorescent antibody assays, widespread subclinical
infection together with the prolonged (2-5 month) incubation period
means that diagnosis of Lyme polyarthritis in dogs still relies upon a
combination of positive serology, exclusion of other causes of poly-
arthritis, and rapid response to treatment with doxycycline. Exclusion
of other causes is difficult in dogs with polyarthritis because the
primary noninfectious differential diagnosis is idiopathic immune-
mediated disease. Diagnosis of Lyme nephritis presents additional
challenges, because the time course and underlying cause of PLN typi-
cally are difficult to determine even with renal histopathologic exami-
nation, and Lyme nephritis usually does not respond to treatment
with doxycycline. Currently, diagnosis most often is based on the
presence of PLN, exclusion of other causes, and a positive C6 anti-
body titer, with or without evidence of membranoproliferative glo-
merulonephritis on histopathology of renal biopsy specimens; no
study has consistently detected spirochete DNA or antigen within renal
biopsy specimens.20,21 In highly endemic areas, the high prevalence of
seroreactivity (>80%) means that a subset of C6 antibody-positive
dogs likely have PLN due to other causes. Therefore, identification of
specific clinicopathological abnormalities that might increase suspicion
for Lyme nephritis would be valuable for diagnosis. Because the overall
prevalence of C6-seropositivity to B. burgdorferi in our region is low
(1.2%),2 our patient population was well suited to a case-control study
because of the ready availability of a number of temporally matched
control dogs.
Although we could not prove that all dogs with antibodies to the C6
antigen had Lyme nephritis, our findings provide strong support that in
northern California, dogs with PLN that also have evidence of exposure to
Borrelia have a distinct clinical syndrome that separates them from dogs
with PLN that have no evidence of exposure to Borrelia. Variables that
were more likely to be present in dogs suspected to have Lyme nephritis
were thrombocytopenia, azotemia, hyperkalemia, hyperphosphatemia,
glucosuria, hematuria, and pyuria. In our study, 20% of dogs that were
C6-seroreactive had physical examination or arthrocentesis findings that
either suggested or confirmed the presence of polyarthritis, which is simi-
lar to the previous report of concurrent lameness or polyarthritis in 26%of
dogs with Lyme nephritis.18 However, most dogs with C6-positive PLN
TABLE 3 Results of testing for other infectious agents (using
serology, PCR, or both) in dogs with PLN that were seroreactive
(n = 40) or seronegative (n = 78) to Borrelia C6 antigen
Borrelia C6
seroreactive
(# positive/
# tested)
Borrelia C6
seronegative
(# positive/
# tested)
Dirofilaria immitis 0/30 0/67
Ehrlichia canis 1/39 4/77
Anaplasma spp. 6/38 2/74
Rickettsia rickettsii 2/18 1/33
Leptospira spp. (titer >1:800) 0/24 3/26
Babesia spp. 0/8 2/21
Bartonella spp. 0/1 0/5
Coccidioides immitis … 1/4
TABLE 4 Medications administered to dogs with PLN in the
14 days before initial examination
Borrelia C6
seroreactive
(n = 40)
Borrelia C6
seronegative
(n = 78)
Antibiotics
Penicillins/cephalosporins 17 30
Fluoroquinolones 11 17
Nitroimidazoles 1 11
Tetracyclines 18 9
Macrolides/lincosamides 0 3
Trimethoprim/sulfa 0 1
Antifungals 0 2
Anti-inflammatories
Glucocorticoidsa 5 10
NSAIDsa 5 15
Other immunosuppressive drugs 2 2
Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs.
aIncludes oral and injectable forms; topical ophthalmic formulations
excluded.
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did not have signs of polyarthritis at the time of evaluation. The prevalence
of fever was low and not associatedwith seroreactivity.
Nearly 70% of seroreactive dogs in our study were thrombocytope-
nic, as previously described.18,22 Thrombocytopenia has been reported
in association with Lyme disease in humans, and an autoimmunemecha-
nism has been proposed based on the detection of antiplatelet autoanti-
bodies.23,24 This finding has been considered controversial because of
the possibility of coinfection with Anaplasma phagocytophilum (although
more recent studies have not shown this finding to be a meaningful con-
founder25), and, in general, thrombocytopenia is considered uncommon
to rare in humans with acute Lyme disease.26 Detectable antibody titers
to Anaplasma, Ehrlichia, or Rickettsia antigens (alone or in combination)
were present in 7 of 40 case dogs, and the possibility of co-pathogens
causing some of the observed clinicopathologic changes cannot be ruled
out (although of these 3 agents, only Ehrlichia causes chronic, persistent
infections that might be associated with PLN, and only 1 case dog
seroreacted to Ehrlichia with an antibody titer of 1:100). Testing for
vector-borne pathogens was not comprehensive in most of the cases,
and convalescent serology was performed inconsistently. Therefore,
undetected coinfections could not be excluded.
The higher prevalence of azotemia, hyperkalemia, and hyper-
phosphatemia in the cases compared with the controls is consistent with
the previous study that described Borrelia-seroreactive PLN as severe
and rapidly progressive.18 This might also explain why higher percent-
ages of case dogs had signs of vomiting, lethargy, weakness, or inappe-
tence reported at the time of initial examination. The presence of
azotemia alone cannot be taken to imply direct renal damage given that
prerenal azotemia as a consequence of dehydration cannot be excluded.
The higher prevalence of glucosuria, hematuria, and pyuria in the cases,
however, suggests that more marked tubuloglomerular damage may
have been present in cases than in controls. Unexpectedly, pyuria was
detected only in the C6-seroreactive dogs, and not in the control dogs,
and therefore the presence of pyuria in dogs with PLN may be helpful to
support a diagnosis of Lyme nephritis in highly endemic areas. Anemia,
neutrophilia, and lymphopenia also were more common in affected dogs
in our study.
The largest case study of Borrelia-seropositive PLN to date was from
the northeastern United States.18 In that study, only 18 of 49 dogs were
tested for antibodies to Borrelia (using indirect immunofluorescence,
ELISA, or Western blot). Glomerular lesions were suspected to be associ-
ated with Lyme disease on the basis of positive serology results in all
tested dogs, residence in a Lyme-endemic area, and a previous case
report that described similar histopathologic findings.27 More than half
of the dogs in that study were ≤5 years of age. No association with age
was seen in our study when the control group was used for comparison,
and overall, a lower percentage of dogs in our study (29/118, 25%) were
≤5 years of age. Labrador and Golden Retrievers comprised over 40% of
affected dogs in both our study and the previous study (24/49 cases),
where the ORs for Labrador and Golden Retrievers as compared to the
hospital background population were 6.4 and 4.9, respectively.18
Retrievers also comprised a large proportion of dogs suspected to have
Lyme nephritis in a subsequent study (21/58 [36%] dogs), but no com-
parison to a reference population was made.21 The reason for the breed
predisposition is unclear; possible explanations include increased recrea-
tion in tick-infested areas by these breeds or an actual genetic predispo-
sition. Large-scale screening of Labrador and Golden Retrievers has not
yielded any evidence of an association between microalbuminuria and
Lyme serology status.28 In humans, certain histocompatibility leukocyte
antigen (HLA) types, including HLA-DR4 and HLA-DR2, are more fre-
quent among patients who develop chronic Lyme arthritis.29-32 Although
a wide range of proteins enter the HLA-DR pathway of antigen presen-
tation, the specific HLA-DR genotype that is present in an individual
appears to be largely responsible for its peptide repertoire.33 There is
increasing evidence that presentation of novel autoantigens, particularly
derivatives of endothelial cell growth factor, matrix metalloproteinase-
10, and apolipoprotein B-100, by HLA-DR molecules to CD4+ T cells
is responsible for the chronic inflammation seen in non-antibiotic-
responsive Lyme arthritis in susceptible individuals.33-37 It is possible that
a similarly abnormal immune response could be responsible for ongoing
inflammation in retriever breeds, leading to secondary immune-mediated
glomerulonephritis. Further investigation is needed to clarify the role of
genetics and specific immune responses in dogs with borreliosis.
Where available, renal histopathology was consistent with ICGN in all
case dogs in our study. We chose to include MGN in this category, even
though Lyme nephritis classically is described as membranoproliferative
glomerulonephritis. Removal of the MGN classification only eliminated
1 case dog from analysis and did not meaningfully alter the statistical ana-
lyses. Interestingly, dogs with MGN previously have been described in
association with putative Lyme nephritis,18 but not all dogs of that report
were tested for Lyme seroreactivity.
Our study had several limitations. The diagnosis of polyarthritis
was based on clinician descriptions, with or without corroborating
synovial fluid analysis, and subclinical polyarthritis may have gone
undetected in some cases. Treatments administered before the time
of examination at our hospital varied widely. Although similar percent-
ages of case and control dogs were treated either with anti-infective
or anti-inflammatory medications before examination, their effects on
clinicopathologic variables could not be completely eliminated. It is
possible that clinical abnormalities detected could have been attribut-
able to etiologies other than Borrelia infection, because the lack of
consistently comprehensive testing in all dogs precluded exclusion of
other causes of disease. Nevertheless, diagnostic evaluations gener-
ally were thorough given that our institution is a tertiary referral hos-
pital. Confirmation of active infection in seropositive dogs was not
possible, and some of these dogs may have been seropositive as a
result of previous subclinical exposure or infection with subsequent
development of PLN from unrelated causes. However, the overall
prevalence of seroreactivity in the geographic region in which the
majority of the dogs in our study resided is low,2 and our experience
is that, when tested, dogs seen at our hospital with clinical abnormali-
ties that are not consistent with those described for Lyme disease
rarely seroreact to Borrelia C6 antigen. The C6 assay is sensitive
(84.2%-96.7%) and specific (96.1%-98.8%) as compared to Western
blotting.38-40 Although false-positive test results are possible in low-
prevalence populations, the selection of a population of at-risk dogs
(ie, those with evidence of PLN) likely increased the positive
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predictive value of Borrelia testing. Lastly, for the diagnosis of PLN, an
arbitrary value of UPCR >5 was selected; occasionally tubular disease
alone may cause UPCRs of this magnitude, and biopsy confirmation of
glomerulonephritis was not obtained in some cases. However, this cut-
off value is similar to criteria that have been used in other studies19
and was intentionally selected to be substantially higher than American
College of Veterinary Internal Medicine guidelines (describing glomeru-
lar proteinuria as persistent UPCR ≥2.041) in order to decrease the
chance of including dogs with tubular proteinuria. A single seropositive
dog with a positive urine culture, which may have confounded UPCR
results, also was included, but UPCR for that dog remained increased
(>15) after treatment of the infection and subsequent negative urine
culture results.
In conclusion, we have provided additional evidence that Lyme
nephritis has clinical features that distinguish it from other causes of
PLN. Factors that may add weight to a diagnosis of Lyme nephritis in
seroreactive dogs with PLN include disease in a retriever or retriever
mix; biochemical evidence of azotemia, hyperkalemia, and hyper-
phosphatemia; findings of thrombocytopenia, anemia, or neutrophilia on
CBC, and the presence of hematuria, glucosuria, and pyuria despite nega-
tive urine culture. Concurrent polyarthritis was not found to be a dis-
tinguishing characteristic in our study, although subclinical polyarthritis
may have been present in some dogs from each group but not recog-
nized. Until further evidence is available to guide appropriate treatment,
given the recognized poor prognosis associated with this syndrome,
combinations of these identified features in C6-seropositive dogs should
prompt aggressive treatment with both doxycycline and immunosup-
pressive drug treatment.22,42
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